C. Bedell

发表

Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer.

D. Rao, N. Senzer, J. Nemunaitis, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors.

Antonina Rait, Esther H Chang, N. Senzer, 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

Phase I Trial of TGF-β2 Antisense GM-CSF Gene-Modified Autologous Tumor Cell (TAG) Vaccine

N. Senzer, J. Nemunaitis, A. Tong, 2011, Clinical Cancer Research.

A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors.

N. Senzer, J. Nemunaitis, T. Fujiwara, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

Management of Diarrhea in Patients with HER2-Positive Breast Cancer Treated with Neratinib: A Case Series and Summary of the Literature

C. Bedell, H. Moore, N. Bagegni, 2021, Oncology and Therapy.

A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies.

J. Baselga, G. Shapiro, E. Kwak, 2010 .

Procoagulant inhibitory properties of paclitaxel poliglumex

N. Senzer, J. Nemunaitis, J. Singer, 2010, International journal of general medicine.

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

Jordi Rodon, Irene Braña, J. Baselga, 2013, Clinical Cancer Research.

Phase II trial of Belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients

N. Senzer, J. Nemunaitis, B. Pappen, 2009, Cancer Gene Therapy.

Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer.

D. Rao, N. Senzer, J. Nemunaitis, 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors.

J. Baselga, G. Shapiro, E. Kwak, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long Term Follow Up: Phase I Trial of bi-shRNA furin/GMCSF DNA/Autologous Tumor Cell Immunotherapy (FANG) in Advanced Cancer

D. Rao, N. Senzer, J. Nemunaitis, 2013 .

Long Term Follow Up: Phase I Trial of bi-shRNA furin/GMCSF DNA/Autologous Tumor Cell Immunotherapy (FANG) in Advanced Cancer

D. Rao, N. Senzer, P. Beitsch, 2013 .

Phase I Trial of "bi-shRNAifurin/GMCSF DNA/Autologous Tumor Cell" Vaccine (FANG) in Advanced Cancer.

D. Rao, N. Senzer, J. Nemunaitis, 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma

J. Nemunaitis, R. Kurzrock, C. Andresen, 2015, Clinical Cancer Research.

Hereditary inclusion body myopathy: single patient response to intravenous dosing of GNE gene lipoplex.

N. Senzer, J. Nemunaitis, W. Gahl, 2011, Human gene therapy.

Hereditary inclusion body myopathy: single patient response to GNE gene Lipoplex therapy

N. Senzer, J. Nemunaitis, W. Gahl, 2010, The journal of gene medicine.

Cancer of the Liver

N. Senzer, J. Nemunaitis, B. Pappen, 2014 .

Phase 1 dose escalation of ONT-10, a therapeutic MUC1 vaccine, in patients with advanced cancer

J. Nemunaitis, C. Bedell, A. Vo, 2013, Journal of Immunotherapy for Cancer.

CPI-613, AN INVESTIGATIONAL NOVEL ANTI-CANCER AGENT, PROVIDES LONG-TERM STABLE DISEASE WITHOUT SIGNIFICANT ADVERSE EFFECTS IN A PATIENT WITH STAGE IV RELAPSED HEPATOCELLULAR CARCINOMA

N. Senzer, C. Bedell, K. Lee, 2012 .

A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors.

N. Senzer, J. Nemunaitis, T. Fujiwara, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

Randomized phase II study of perifosine in combination with capecitabine versus capecitabine alone in patients with second- or third-line metastatic colon cancer.

L. Campos, C. Bedell, D. Richards, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.